Lorcaserin + Placebo
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity
Conditions
Obesity
Trial Timeline
Jan 1, 2015 → Jun 1, 2017
NCT ID
NCT02388568About Lorcaserin + Placebo
Lorcaserin + Placebo is a pre-clinical stage product being developed by Eisai for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT02388568. Target conditions include Obesity.
What happened to similar drugs?
20 of 20 similar drugs in Obesity were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02388568 | Pre-clinical | Completed |
Competing Products
20 competing products in Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 35 |
| MK0557 | Merck | Phase 3 | 40 |
| AMG 786 | Amgen | Phase 1 | 29 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 39 |
| Tirzepatide | Eli Lilly | Phase 2 | 42 |
| exenatide + Placebo | Eli Lilly | Approved | 43 |
| Brenipatide | Eli Lilly | Phase 1 | 36 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 47 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 32 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 30 |
| PG-102 | Rani Therapeutics | Phase 1 | 26 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 40 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 29 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 27 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 29 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 29 |
| Tirzepatide | Eli Lilly | Approved | 50 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 26 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 43 |